Anonimous: Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 352: 930–942, 1998.
2.
GoldhirschA., GlickJ.H., GelberR.D., CoatesA.S., SennH.J.: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol, 19: 3817–3827, 2001.
3.
EifelP., AxelsonJ.A., CostaJ., CrowleyJ., CurranW.J.Jr., DeshlerA., FultonS., HendricksC.B., KemenyM., KornblithA.B., LouisT.A., MarkmanM., MayerR., RoterD.: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst, 93: 979–989, 2001.
4.
BonneterreJ., RocheH., MonnierA., SerinD., FargeotP., GuastalaJ.P., RiosM., NamerM., CulineS., TubianaM., AssadourianS., GaudinI.: Taxotere (TXT) versus 5-fluorouracil + navelbine (FUN) as second-line chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) (preliminary results) (Meeting abstract). Proc ASCO, 16: A564, 1997.
5.
NabholtzJ.M., SennH.J., BezwodaW.R., MelnychukD., DeschenesL., DoumaJ., VandenbergT.A., RapoportB., RossoR., Trillet-LenoirV., DrbalJ., MolinoA., NortierJ.W., RichelD.J., NagykalnaiT., SiedleckiP., WilkingN., GenotJ.Y., HupperetsP.S., PannutiF., SkarlosD., TomiakE.M., MurawskyM., AlaklM., AaproM.: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy: 304 study group. J Clin Oncol, 17: 1413–1424, 1999.
6.
SjostromJ., BlomqvistC., MouridsenH., PluzanskaA., Ottosson-LonnS., BengtssonN.O., OstenstadB., MjaalandI., Palm-SjovallM., WistE., ValvereV., AndersonH., BerghJ.: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer, 35: 1194–201, 1999.
7.
ChanS., FriedrichsK., NoelD., PinterT., Van BelleS., VorobiofD., DuarteR., GilG.M., BodrogiI., MurrayE., YelleL., Von MinckwitzG., KorecS., SimmondsP., BuzziF., GonzalezM.R., RichardsonG., WalpoleE., RonzoniM., MurawskyM., AlaklM., RivaA.: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol, 17: 2341–2354, 1999.
8.
NabholtzJ.M., FalksonG., CamposS.M., SzantoJ., MartinM., ChanS., PienkowskiT., BezwodaW.R., ZaluskyJ., KrakowskiM., VorobiofD., LeonardR., KennedyI., AzliN., MurawskyM., RivaA., PuillartP.: A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC. Proc ASCO, 18: 485, 1999.
9.
JassemJ., PienkowskiT., PluzanskaA., JelicS., GorbunovaV., Mrsic-KrmpoticZ., BerzinsJ., NagykalnaiT., WiglerN., RenardJ., MunierS., WeilC.: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer. Final results of a randomized phase III multicenter trial. J Clin Oncol, 19: 1707–1715, 2001.
10.
MackeyJ., PatersonA., DirixL., DewarJ., ChapL., MartinM., ChanS., TangS.C., DuganW., GilM., ZaluskyJ., RusselC., VogelC., EfremidisA., AppiaF., BruneiE., HattevilleL., AzliN., NabholtzJ.M.: Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (PTS) with metastatic breast cancer. Proc ASCO, 21: 137, 2002.
11.
NabholtzJ.M., MackeyJ.R., SmylieM., PatersonA., NoelD.R., Al TweigeriT., TonkinK., NorthS., AzliN., RivaA.: Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol, 19: 314–321, 2001.
12.
NabholtzJ.M., PienkowskiT., MackeyJ., PawlikiM., GuastallaJ.P., VogelC., WeaverC., WalleyB., MartinM., ChapL., TomiakE.M., JuhosE., GuevinR., HowellA., HainsworthJ., FornanderT., BlitzS., GazelS., LoretC., RivaA.: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc ASCO, 21: 141, 2002.
13.
NSBAP Investigators,: The effect of primary tumor response of adding sequential taxotere to adriamycin and cyclophosphamide: preliminary results from NSABP protocol B-27. Breast Cancer Res Treat, 69: 5, 2001.
